Evotec and Bristol Myers Squibb's Protein Degradation Partnership Yields Progress

Evotec SE has announced significant advancements in its collaboration with Bristol Myers Squibb. This progress includes the development of a pipeline focused on molecular glue degraders for addressing unmet medical needs. Consequently, Evotec is set to receive a total of $75 million based on performance and program achievements.

The partnership, which began in 2018, leverages Evotec’s high-performance screening and AI-driven data analytics alongside Bristol Myers Squibb’s library of cereblon E3 ligase modulators (CELMoDs™). The collaboration seeks to discover new molecular glue degraders, targeting significant areas in oncology and beyond. The pipeline’s growth underpins joint efforts between both companies.

Evotec’s Chief Scientific Officer, Dr. Cord Dohrmann, underlined the potential of molecular glue degraders to deliver groundbreaking products, emphasizing the value of their systematic approach in collaboration with Bristol Myers Squibb.